American Association for Cancer Research

Table 1

Baseline clinical characteristics of the study subjects (n = 26)

Characteristic	Intervention (n = 15)	Control (n = 11)	P ^a
Age
Median (range)	61 (51–71)	61 (53–70)
Mean ± SE^b	62.3 ± 1.9	62.0 ± 1.8	0.92
Race
African American	2	3
Caucasian American	13	8	0.62
Baseline clinical stage^c
T_1C	10	4
T_2A	2	4
T_2B	3	3	0.13^a
Baseline Gleason score
≤6	11	5
>6	4	6	0.23
Baseline plasma PSA (ng/ml)	6.89 ± 0.81^b	6.74 ± 0.88	0.89

Characteristic	Intervention (n = 15)	Control (n = 11)	P ^a
Age
Median (range)	61 (51–71)	61 (53–70)
Mean ± SE^b	62.3 ± 1.9	62.0 ± 1.8	0.92
Race
African American	2	3
Caucasian American	13	8	0.62
Baseline clinical stage^c
T_1C	10	4
T_2A	2	4
T_2B	3	3	0.13^a
Baseline Gleason score
≤6	11	5
>6	4	6	0.23
Baseline plasma PSA (ng/ml)	6.89 ± 0.81^b	6.74 ± 0.88	0.89

P is for comparing the distribution of T₁versus T₂ in the two groups.

Mean + SE.

American Urologic Association (AUA) Staging System: T_1C, tumor on needle biopsy of nonpalpable mass; T_2A, tumor involving one lobe; T_2B, tumor involving both lobes.

View Large

This Feature Is Available To Subscribers Only